SUO 2018: A Phase 3, Randomized, Double Blind, Placebo Controlled Study of Enzalutamide in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of PROSPER by Prior Definitive Surgery
Phoenix, Arizona (UroToday.com) The PROSPER trial, published in the New England Journal of Medicine in June 2018, demonstrated that in med with non-metastatic castrate resistant prostate cancer with a rising PSA, treatment with enzalutamide led to a 71% lower risk of metastasis or death than placebo.
SUO 2018: Before and After Clinical CR from NAC
Phoenix, Arizona (UroToday.com) Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiation is the standard of care for urothelial carcinoma in patients with muscle-invasive bladder cancer (MIBC). Both cystectomy and chemoradiation carry potential short and long-term toxicity and quality of life implications. Sparing patients RC or chemoradiation after NAC without compromising oncologic outcomes would improve quality of life and decrease morbidity.
SUO 2018: There Is Still a Role for Cytoreduction
Phoenix, Arizona (UroToday.com) Dr. Leibovich began the presentation explaining why there is still a role for cytoreduction in metastatic renal cell carcinoma (RCC). The benefit in overall survival of cytoreductive nephrectomy in the cytokine era is well known.1,2 These relatively older data demonstrated that cytoreductive nephrectomy entailed a 5 months survival advantage and that 19.6% of the patients were still alive at 5 years.
SUO 2018: Qualitative and Quantitative Evidence of Sipuleucel-T Induced PAP and PA2024 Specific CD8+ Cytolytic Response and its Association with Overall Survival
Phoenix, Arizona (UroToday.com) In this oral abstract presentation, Dr. Kibel presented a multi-institutional analysis assessing sipuleucel-T induced peripheral cellular and humoral immune response to prostatic acid phosphatase and/or PA2024. Previous studies have demonstrated that CD4 and CD8 T cells at the prostate tumor rim after neoadjuvant sipuleucel-T leads to an immune response that may mediate clinical survival benefits.
SUO 2018: Changing Practice in High Risk Prostate Cancer Using Novel Trial Design: The STAMPEDE Study
Phoenix, Arizona (UroToday.com) Noel Clarke began his talk highlighting the multi-arm, multi-stage (MAMS) approach of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial design, and how it changed practice in high-risk prostate cancer.
He acknowledged the STAMPEDE investigators and talked about how there was a “need for speed and a new approach” to test new drugs especially in prostate cancer where the demand for evaluation of new therapies was large.
SUO 2018: Impact of Robotics - The Changing Face of Urologic Oncologic Surgery from 2000-2018
Phoenix, Arizona (UroToday.com) Dr. Gill presented work from his department titled “The Changing Face of Urologic Oncologic Surgery from 2000-2018 (63,141 patients) - Impact of Robotics”. This work evaluated the current status of urologic oncologic surgery by comparing outcomes of open and robotic surgery over the past 17 years. The five key questions that were studied through this systemic review were a comparison of open and robotic surgery regarding penetrance in the field, peri-operative outcomes, oncologic outcomes and survival, functional outcomes and financial cost.
SUO 2018: Phase 2 Study of Pembrolizumab Monotherapy for High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG): Results from Keynote-057
Phoenix, Arizona (UroToday.com) Previous studies have demonstrated that constitutive PD-1 activation has been implicated in BCG resistance. While radical cystectomy is a standard option for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), it is associated with a high rate of perioperative morbidity and has a significant impact on patient quality of life.